22nd June 2015

Roche Diagnostics unveils latest innovations at EuroMedLab Paris 2015

More than 10,000 visitors will descend on Paris this month to see Roche Diagnostics launch its latest innovations - the cobas e801 analyser and cobas 8000 modular analyser series connection module - the next generation in high value diagnostic technology from the world’s largest biotech company.

The launch event will take place on Monday, June 22 at EuroMedLab Paris 2015. Roche Diagnostics will also be running a series of educational workshops throughout the conference on recent scientific findings in oncology, infectious diseases, cardiology and fertility.

Christopher Parker, Managing Director of Roche Diagnostics UK and Ireland, said: “It is our goal to continue to deliver the most comprehensive systems in diagnostics. In doing so we want to enable quicker and more accurate diagnosis which in turn will mean earlier prognosis and more personalised solutions for patients.”

Paul Skingley, Director of Hospital InVitro Diagnostics at Roche Diagnostics UK and Ireland, said: “We are delighted to unveil some of our very latest diagnostic products. These will continue to position Roche with the youngest, fastest and broadest portfolio of innovations that empower.”



Notes to Editor:

For media enquiries please call +44 (0)20 7054 9974 or email roche@weareicg.com

About EuroMedLab Paris 2015

  • The EuroMedLab will take place at Le Palais des Congrès, Paris, France from 21 – 25 June
  • EuroMedLab Paris 2015 represents one of the most influential in-vitro diagnostics events worldwide.
  • The title of this year’s conference is Innovation that empowers – because you matter.
  • The conference is expected to attract more than 10,000 visitors, who will have the opportunity to learn more about the latest scientific findings in laboratory medicine and the important advances they will mean for physicians and – first and foremost – for patients.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making
important contributions to global health for more than a century. Twenty-eight medicines developed
by Roche are included in the World Health Organization Model Lists of Essential Medicines, among
them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in
R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned
member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.